Replimune Group, Inc. Common Stock REPL
i
Market datapartial · fetched 2026-11-10T22:19:14.435Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:56:50.468128517Z
FundamentalsAlpha Vantage · unavailable
Replimune Group, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 22.54 | 297.2% | 12.2% | |||
| 45Δ | ||||||
| 50Δ | 23.37 | 99.4% | 3.9% | 23.85 | 241.1% | 7.6% |
| 55Δ | 23.10 | 101.3% | 3.3% | |||
| 60Δ | 22.84 | 100.5% | 2.8% | 24.68 | 190.7% | 4.5% |
| 65Δ | 22.59 | 97.9% | 2.2% | 25.30 | 193.1% | 3.7% |
| 70Δ | 25.91 | 194.5% | 3.0% | |||
| 75Δ | 29.03 | 303.3% | 3.5% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.54
- IV
- 297.2%
- B/E move
- 12.2%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 23.37
- IV
- 99.4%
- B/E move
- 3.9%
- Pseudo strike
- 23.85
- IV
- 241.1%
- B/E move
- 7.6%
55Δ
- Pseudo strike
- 23.10
- IV
- 101.3%
- B/E move
- 3.3%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 22.84
- IV
- 100.5%
- B/E move
- 2.8%
- Pseudo strike
- 24.68
- IV
- 190.7%
- B/E move
- 4.5%
65Δ
- Pseudo strike
- 22.59
- IV
- 97.9%
- B/E move
- 2.2%
- Pseudo strike
- 25.30
- IV
- 193.1%
- B/E move
- 3.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.91
- IV
- 194.5%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 29.03
- IV
- 303.3%
- B/E move
- 3.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 315.88% | |
| 137.36% | |
| 206.58% | |
| 198.45% | |
| 229.11% | |
| 180.31% | |
| 158.19% | |
| 151.19% | |
| 135.18% | |
| 76.18% |
Biotechnology
RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body…
More →RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is…
More →RLAY
Relay Therapeutics, Inc. is a clinical-stage precision drug company. The company is headquartered in Cambridge, Massachusetts.
More →RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to treat central nervous system (CNS) diseases and other disorders in the…
More →RNAC
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and…
More →ROIV
Description unavailable
More →